+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030- Product Image
Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030- Product Image
Sale

Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716081
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The diabetes associated ophthalmic treatment market is experiencing rapid transformation as clinical innovation, digital integration, and global policy changes reshape therapeutic strategies and investment opportunities. For decision-makers, effective navigation of this dynamic space demands an understanding of shifting care models, regional nuances, and the interplay between clinical efficacy and economic sustainability.

Market Snapshot: Diabetes Associated Ophthalmic Treatment Market

The diabetes associated ophthalmic treatment market grew from USD 6.18 billion in 2024 to USD 6.74 billion in 2025. It is expected to continue growing at a CAGR of 8.67%, reaching USD 10.19 billion by 2030. Driven by increased prevalence of diabetic eye disease and advances in pharmacotherapy, this sector attracts sustained interest from diverse healthcare stakeholders. Heightened demand for targeted therapies and real-world outcome data is fueling competitive development and market expansion worldwide.

Scope & Segmentation

This report provides a comprehensive overview of the diabetes associated ophthalmic treatment market across key solution categories, patient types, and regions.

  • Treatment Types: Includes anti-VEGF agents (aflibercept, bevacizumab, brolucizumab, faricimab, ranibizumab), corticosteroids (dexamethasone implant, fluocinolone implant, triamcinolone), laser therapies (focal/grid photocoagulation, panretinal photocoagulation), and surgical interventions.
  • Routes of Administration: Encompasses intravitreal injections (prefilled syringe, vial), systemic (intravenous, oral), and topical approaches (eye drops, ointments).
  • Patient Types: Segmented by type 1 and type 2 diabetes, acknowledging their divergent disease trajectories and therapeutic needs.
  • End User Types: Examines engagement patterns across ambulatory surgical centers, hospitals, ophthalmology clinics, and retail pharmacies.
  • Regions Covered: Details dynamic trends across the Americas (focusing on major markets such as the US, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with major and emerging economies included), and Asia-Pacific (addressing growth in countries like China, India, Japan, Australia, and Southeast Asia).
  • Key Players: Assesses activities and recent developments by leading firms, including F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Bayer AG, Novartis AG, AbbVie Inc., Alcon Inc., Bausch Health Companies, Sandoz International, Chengdu Kanghong Pharmaceutical, and Intas Pharmaceuticals.

Key Takeaways for Decision-Makers

  • The therapeutic landscape for diabetic eye disease is diversifying, with a shift from single-pathway interventions to multi-modal approaches that enable personalization of care.
  • Sustained-release technologies and depot formulations lower patient treatment burden and improve adherence, particularly in chronic management scenarios.
  • Artificial intelligence and digital diagnostics are streamlining early detection of microvascular changes, supporting earlier intervention and improved clinical outcomes.
  • Market access and adoption are increasingly shaped by regional reimbursement models, regulatory harmonization efforts, and disparities in healthcare infrastructure, requiring tailored strategies by geography.
  • Collaboration between pharmaceutical and device manufacturers is intensifying, supporting the development of integrated delivery systems and combination therapies.
  • Payer demand for evidence-based, value-driven reimbursement is accelerating use of real-world data and value-based contracting within the sector.

Tariff Impact on Ophthalmic Treatment Supply Chains

Recent US tariffs on pharmaceutical imports and medical devices have heightened input costs and driven manufacturers to reassess supply sources. Companies responding to these pressures are shifting production closer to domestic markets, accelerating value-based contracts, and exploring greater supplier diversification. These trade policy changes are influencing pricing negotiations and altering distribution pathways for diabetes associated ophthalmic treatments.

Methodology & Data Sources

Research integrates secondary sources—including peer-reviewed publications, regulatory agency documents, industry white papers, and corporate filings—with insights from structured interviews with retina specialists, payers, and healthcare economists. Quantitative modeling utilizes robust segmentation and sensitivity analysis to validate findings and conclusions.

Why This Report Matters

  • Equips strategy leaders with actionable intelligence to inform investment, supply chain, and partnership decisions in the evolving ophthalmic diabetes market.
  • Enables more effective targeting of product development and commercialization efforts through granular patient and regional segmentation insights.
  • Supports risk mitigation planning by clarifying regulatory, economic, and technology trends shaping near- and mid-term market trajectories.

Conclusion

Advances in science, technology, and care models continue to shape the diabetes associated ophthalmic treatment market. Stakeholders leveraging these market insights can prioritize resources, forge effective partnerships, and deliver improved patient outcomes within a rapidly evolving industry.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-VEGF
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Brolucizumab
8.2.4. Faricimab
8.2.5. Ranibizumab
8.3. Corticosteroids
8.3.1. Dexamethasone Implant
8.3.2. Fluocinolone Implant
8.3.3. Triamcinolone
8.4. Laser Therapy
8.4.1. Focal/Grid Photocoagulation
8.4.2. Panretinal Photocoagulation
8.5. Surgical Intervention
9. Diabetes Associated Ophthalmic Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravitreal Injection
9.2.1. Prefilled Syringe
9.2.2. Vial
9.3. Systemic
9.3.1. Intravenous
9.3.2. Oral
9.4. Topical
9.4.1. Eye Drops
9.4.2. Ointments
10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type
10.1. Introduction
10.2. Type 1 Diabetes
10.3. Type 2 Diabetes
11. Diabetes Associated Ophthalmic Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Ophthalmology Clinics
11.5. Retail Pharmacies
12. Americas Diabetes Associated Ophthalmic Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. Regeneron Pharmaceuticals, Inc.
15.3.3. Bayer AG
15.3.4. Novartis AG
15.3.5. AbbVie Inc.
15.3.6. Alcon Inc.
15.3.7. Bausch Health Companies Inc.
15.3.8. Sandoz International GmbH
15.3.9. Chengdu Kanghong Pharmaceutical Group Co., Ltd
15.3.10. Intas Pharmaceuticals Ltd
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 69. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 70. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 74. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 75. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 79. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 130. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 135. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 140. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 145. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 160. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 161. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 164. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 165. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 166. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 170. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 175. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 176. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 210. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 215. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 216. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 230. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 231. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 232. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 234. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 235. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 236. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 240. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 245. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 246. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 270. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 275. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 276. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 280. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Diabetes Associated Ophthalmic Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Sandoz International GmbH
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd
  • Intas Pharmaceuticals Ltd

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.74 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.19 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report - Product Image

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030 - Product Image

Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030

  • Report
  • 110 Pages
  • Global
From
Smart Insulin Pens & Pumps Market by Product Type, Treatment Type, Distribution Channel, Diabetes Type, End User - Global Forecast to 2030 - Product Image

Smart Insulin Pens & Pumps Market by Product Type, Treatment Type, Distribution Channel, Diabetes Type, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Needle Free Diabetes Care Market by Application, Product Type, Age Group, End User, Distribution Channel, Technology - Global Forecast to 2030 - Product Image

Needle Free Diabetes Care Market by Application, Product Type, Age Group, End User, Distribution Channel, Technology - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From

About the Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment market encompasses a range of medical procedures, devices, and medications utilized in the management and care of eye conditions associated with diabetes, specifically diabetic retinopathy and diabetic macular edema. Diabetic retinopathy involves changes to retinal blood vessels that can cause them to bleed or leak fluid, distorting vision. Treatments for these conditions range from laser surgery to control bleeding to the administration of anti-VEGF drugs, which help to reduce abnormal blood vessel growth and swelling. Intravitreal injections of steroids can also be utilized for their anti-inflammatory effects. Additionally, there is a growing interest in the development and use of novel drug delivery systems and surgical instruments to improve the precision and efficacy of treatments. Furthermore, technological advancements in optical coherence tomography (OCT) aids in the early detection and management of diabetic eye diseases by providing high-resolution images of the retina. Regular screening among diabetic patients is crucial for early intervention and has become an integral part of diabetes care, helping to prevent vision loss. Several companies have established positions in the market, which include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Abbott. These companies are involved in the production of therapeutics like anti-VEGF injections, as well as manufacturing devices and supplies for laser treatments and surgeries tailored to mitigate the ocular complications that arise from diabetes. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.